首页> 外国专利> METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT

METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT

机译:靶向微生物的方法,组成及其对肺癌的免疫途径

摘要

It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.
机译:已经发现,肺肿瘤的生长与局部微生物群的失调有关,包括增加的总细菌负荷和减少的气道细菌多样性。在肺部,共生细菌是非致病性的,并且在健康个体中以低得多的密度定居在肺组织中,它通过肿瘤浸润性免疫细胞引起慢性炎症和肺癌恶化。因此,靶向肺微生物群及其响应的免疫途径可用于治疗肺癌。公开了通过特异性靶向对象中的共生细菌而针对对象中的肺微生物群及其响应的免疫途径的组合物和方法。通常,所述方法包括给予有效量的一种或多种治疗剂,例如减少局部细菌负荷,阻断或消耗肿瘤浸润免疫细胞和/或局部抑制一种或多种细胞因子或趋化因子的抗生素。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号